Department of Medicine, Divisions of Nephrology and Multi-Organ Transplant Program, McGill University Health Centre, Montreal, QC, Canada.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nephrol Dial Transplant. 2018 Jul 1;33(7):1251-1259. doi: 10.1093/ndt/gfy010.
The use of machine perfusion (MP) in kidney transplantation lowers delayed graft function (DGF) and improves 1-year graft survival in some, but not all, grafts. These associations have not been explored in grafts stratified by the Kidney Donor Profile index (KDPI).
We analyzed 78 207 deceased-donor recipients using the Scientific Registry of Transplant Recipients data from 2006 to 2013. The cohort was stratified using the standard criteria donor/expanded criteria donor (ECD)/donation after cardiac death (DCD)/donation after brain death (DBD) classification and the KDPI scores. In each subgroup, MP use was compared with cold storage.
The overall DGF rate was 25.4% and MP use was associated with significantly lower DGF in all but the ECD-DCD donor subgroup. Using the donor source classification, the use of MP did not decrease death-censored graft failure (DCGF), except in the ECD-DCD subgroup from 0 to 1 year {adjusted hazard ratio [aHR] 0.56 [95% confidence interval (CI) 0.32-0.98]}. In the ECD-DBD subgroup, higher DCGF from 1 to 5 years was noted [aHR 1.15 (95% CI 1.01-1.31)]. Also, MP did not lower all-cause graft failure except in the ECD-DCD subgroup from 0 to 1 year [aHR = 0.59 (95% CI 0.38-0.91)]. Using the KDPI classification, MP did not lower DCGF or all-cause graft failure, but in the ≤70 subgroup, higher DCGF [aHR 1.16 (95% CI 1.05-1.27)] and higher all-cause graft failure [aHR 1.10 (95% CI 1.02-1.18)] was noted. Lastly, MP was not associated with mortality in any subgroup.
Overall, MP did not lower DCGF. Neither classification better risk-stratified kidneys that have superior graft survival with MP. We question their widespread use in all allografts as an ideal approach to organ preservation.
在肾脏移植中使用机器灌注(MP)可以降低延迟移植物功能障碍(DGF)并提高某些移植物的 1 年移植物存活率,但并非所有移植物都如此。这些关联在根据肾脏供体概况指数(KDPI)分层的移植物中尚未得到探索。
我们使用 2006 年至 2013 年 Scientific Registry of Transplant Recipients 数据对 78207 例已故供体受者进行了分析。该队列根据标准供体/扩展标准供体(ECD)/心脏死亡后供体(DCD)/脑死亡后供体(DBD)分类和 KDPI 评分进行分层。在每个亚组中,将 MP 与冷藏进行比较。
总体 DGF 发生率为 25.4%,除 ECD-DCD 供体亚组外,MP 的使用与 DGF 显著降低相关。使用供体来源分类,除 ECD-DCD 亚组外,MP 的使用并未降低死亡相关移植物失败(DCGF),在 ECD-DCD 亚组中,1 年至 5 年的 DCGF 时间点[调整后的危险比(aHR)0.56(95%置信区间(CI)0.32-0.98)]显著降低。在 ECD-DBD 亚组中,1 年至 5 年的 DCGF 时间点更高[aHR 1.15(95%CI 1.01-1.31)]。此外,除 ECD-DCD 亚组外,MP 并未降低所有原因的移植物失败,在 ECD-DCD 亚组中,1 年至 5 年的所有原因移植物失败时间点[aHR=0.59(95%CI 0.38-0.91)]。使用 KDPI 分类,MP 并未降低 DCGF 或所有原因的移植物失败,但在≤70 亚组中,更高的 DCGF[aHR 1.16(95%CI 1.05-1.27)]和更高的所有原因移植物失败[aHR 1.10(95%CI 1.02-1.18)]。最后,MP 在任何亚组中均与死亡率无关。
总体而言,MP 并未降低 DCGF。两种分类都没有更好地对具有优越移植物存活率的移植物进行风险分层。我们对其在所有同种异体移植物中作为器官保存理想方法的广泛应用提出质疑。